Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.990 +0.060 (+3.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
News headline image
Take Your Ocugen Stock Profits and Run If You Haven’t Already ↗
Though OCGN stock provided lifechanging profitability to speculators, these Cinderella stories usually come to a devastating end. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
News headline image
OCGN Stock: The Big FDA News Lifting Ocugen Shares Today ↗
OCGN stock is on the move today as biopharma Ocugen confirms its intent to submit an EUA for Covaxin in June 2021. 
Via InvestorPlace
News headline image
24 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets.... 
Via Benzinga
News headline image
2 Reasons to Avoid Ocugen Stock -- and 1 Reason to Considering Buying It ↗
The company has a path to success in the COVID-19 vaccine market, but it might be more of an uphill climb than some investors realize. 
Via The Motley Fool
News headline image
Here's What Is Going On With Ocugen (OCGN) Stock ↗
Shares of Ocugen Inc. (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, fell 3.7% in Wednesday’s regular trading session. What... 
Via Benzinga
News headline image
FDA May Not Review New COVID-19 Vaccine Emergency Use Requests ↗
The FDA, on Tuesday, said that it might decline to review and process new emergency use authorization (EUA) requests for COVID-19 vaccines for the rest of the pandemic... 
Via Benzinga
News headline image
Bharat Biotech's US Partner Ocugen Submits Covaxin Master File for FDA Review ↗
Ocugen Inc (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, has submitted a “Master File” to the FDA... 
Via Benzinga
News headline image
Take Profits If You Own Ocugen Stock, but Now’s Not the Time to Buy ↗
We don't know if the FDA will authorize emergency use for Covaxin. Therefore OCGN stock is a high risk investment. 
Via InvestorPlace
News headline image
Ocugen vs. Inovio: Where Is the Smart Money Going? ↗
They're both seeking share in the vaccine market. 
Via The Motley Fool
News headline image
Ocugen Faces Long Odds Before Gaining From Its Covid-19 Support Role ↗
Ocugen has skin in the Covid-19 vaccine game. But the company faces long odds on its partnership providing a long-term boost for OCGN stock. 
Via InvestorPlace
News headline image
Stay On The Sidelines With Ocugen Stock ↗
The small biopharmaceutical company has a promising Covid-19 vaccine, but the timing of its approval remains a question mark for OCGN stock. 
Via InvestorPlace
News headline image
Ocugen Stock Is Left Behind As the U.S. Emerges From the Pandemic ↗
There seems to be no need for Covaxin in the U.S. and there are no indications that the U.S. is considering approving it. Consequently, OCGN stock is worth shorting. 
Via InvestorPlace
News headline image
Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner? ↗
It's still really early. 
Via The Motley Fool
News headline image
Ocugen or Vaxart: Which Will Take Investors Further? ↗
These two high-flying biotechs are vying for the same market. 
Via The Motley Fool
News headline image
Ocugen Has a Longer Road To Paying off Than People Think ↗
Even after good news in recent days, OCGN stock is right back where it started. And that still doesn't create a buying opportunity. 
Via InvestorPlace
News headline image
Can Ocugen Overcome This Major Hurdle? ↗
It will determine whether the shares sink or skyrocket in the long term. 
Via The Motley Fool
News headline image
Take a Look at Ocugen’s Work on Eye Diseases, Not Just Their Vaccine Partnership ↗
With clinical data to support Ocugen's product candidate to treat multiple eye conditions, OCGN stock isn't just your typical "vaccine stock." 
Via InvestorPlace
News headline image
Could Ocugen Be a Millionaire Maker Stock? ↗
This coronavirus vaccine drugmaker has made investors rich in a very short period. Can it sustain its run? 
Via The Motley Fool
News headline image
FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children ↗
The FDA’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10... 
Via Benzinga
News headline image
This Is Why Ocugen Crashed Despite Apparent Good News ↗
Ocugen released a bunch of seemingly positive news in recent days. Yet OCGN stock tanked anyway. Here's why you should stay away from it. 
Via InvestorPlace
News headline image
3 Investments That Turned $35,000 Into $1 Million (or More) in Just 6 Months ↗
One security grew $35,000 into more than $9 million since early November. 
Via The Motley Fool
Topics Stocks
News headline image
Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript ↗
OCGN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
OCGN Stock: Why Red-Hot Ocugen Is Plunging Again Today ↗
Ocugen (OCGN) stock taking a beating on Friday following the release of the biopharmaceutical company's earnings report for Q1 2021. 
Via InvestorPlace
News headline image
Why Ocugen Stock Is Tanking Today ↗
Investors didn't get what they wanted in the biotech's Q1 update. 
Via The Motley Fool
News headline image
Ocugen Stock Has a Big Pullback Coming, and That Will Be Your Chance ↗
OCGN Stock had a nice run in recent weeks but faces risks of a sharp pullback that could lead to paper losses for speculators. 
Via InvestorPlace
News headline image
Ocugen Stock Is a Risky Proposition Despite Its High Valuation ↗
OCGN stock soared on a deal to commercialize Bharat Biotech’s Covaxin in the U.S., but the rollout comes with a lot of challenges. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Assertio Holdings (NASDAQ:ASRT) shares moved upwards by 32.42% to $0.66 during Friday's pre-market session. The company's market cap stands at $114.5... 
Via Benzinga
News headline image
Does Ocugen Have a Real Shot at the U.S. COVID Vaccine Market? ↗
The biotech faces some big challenges. 
Via The Motley Fool
News headline image
Better Vaccine Stock: Ocugen or Vaxart? ↗
Here's how the biotechs compare on several key fronts. 
Via The Motley Fool
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.